Reneurogen, LLC
Publicly observedElm Grove, United States
Seen in a public record (e.g. a government grant database); not otherwise verified.
Details and provenance
| Item | Value | Source | Status |
|---|---|---|---|
| Country | US | NIH RePORTER (opens in a new tab) 28 Sept 2026 | Publicly observed |
| City / locality | Elm Grove | NIH RePORTER (opens in a new tab) 28 Sept 2026 | Publicly observed |
| Name | Reneurogen, LLC | NIH RePORTER (opens in a new tab) 28 Sept 2026 | Publicly observed |
| UEI (U.S. federal entity ID) | JSKMSKNBLN89 | NIH RePORTER (opens in a new tab) 28 Sept 2026 | Publicly observed |
Recorded events
- Grant22 Sept 2025Publicly observed
NIH SBIR/STTR award: KYC, an inhibitor of sickle cell disease's vicious cycle in vaso-occlusive crisis and pain
USD 966,985.00 · National Heart Lung and Blood Institute · Source: NIH RePORTER (opens in a new tab)
- Grant22 Sept 2025Publicly observed
NIH SBIR/STTR award: KYC, an inhibitor of sickle cell disease's vicious cycle in vaso-occlusive crisis and pain
USD 1,045,688.00 · National Heart Lung and Blood Institute · Source: NIH RePORTER (opens in a new tab)
- Grant15 Jun 2023Publicly observed
NIH SBIR/STTR award: Development of a systems pharmacology agent for treatment of bronchopulmonary dysplasia
USD 50,000.00 · National Heart Lung and Blood Institute · Source: NIH RePORTER (opens in a new tab)
Information only — not investment advice or an endorsement. Is this your company? Submit or update its details or request a correction.